Dopamine d1 receptors, regulation of gene expression in the brain, and neurodegeneration

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 5, 2010, Pages 526-538

  Cadet, Jean Lud ^a   Jayanthi, Subramaniam ^a   Mccoy, Michael T ^a   Beauvais, Genevieve ^a   Cai, Ning Sheng ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Amphetamines; Ap 1; Apoptosis; Basal ganglia; Cocaine; Da receptors; Egr; Signal transduction

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DYNORPHIN; EARLY GROWTH RESPONSE FACTOR 2; EARLY GROWTH RESPONSE FACTOR 3; ENKEPHALIN; FIBROBLAST GROWTH FACTOR 2; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; NEUROPEPTIDE Y; NEUROTENSIN; NUCLEAR RECEPTOR NUR77; PROTEIN C FOS; PROTEIN C JUN; SOMATOSTATIN; SUBSTANCE P; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; TRANSCRIPTION FACTOR ZIF268; UNCLASSIFIED DRUG;

ARTICLE; BASAL GANGLION; BRAIN; CORPUS STRIATUM; GENE EXPRESSION; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; NERVE DEGENERATION; NONHUMAN; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 78649238972     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793361496     Document Type: Article

References (162)

1. Harley, C.W. Norepinephrine and dopamine as learning signals. Neural Plast., 2004, 11, 191-204.
2. Fallon, J.H. Topographic organization of ascending dopaminergic projections. Ann. NY Acad. Sci., 1988, 537, 1-9.
3. Jimenez-Castellanos, J.; Graybiel, A.M. Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix. Neuroscience, 1987, 23, 223-242.
4. Bjorklund, A.; Dunnett, S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci., 2007, 30, 194-202.
5. Chinta, S.J.; Andersen, J.K. Dopaminergic neurons. Int. J. Biochem. Cell Biol., 2005, 37, 942-946.
6. Cadet, J.L. A unifying theory of movement and madness: involvement of free radicals in disorders of the isodendritic core of the brainstem. Med. Hypotheses, 1988, 27, 59-63.
7. Carlsson, A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry, 2006, 39(Suppl 1), S10-S14.
8. Hornykiewicz, O. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener. Dis., 2008, 5, 114-117.
9. Wise, R.A. Roles for nigrostriatal--not just mesocorticolimbicdopamine in reward and addiction. Trends Neurosci., 2009, 32, 517-524.
10. Fahn, S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov. Disord., 2008, 23(Suppl 3), S497-S508.
11. Peroutka, S.J.; Snyder, S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry, 1980, 137, 1518-1522.
12. Kebabian, J.W.; Petzold, G.L.; Greengard, P. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the dopamine receptor. Proc. Natl. Acad. Sci. USA, 1972, 69, 2145-2149.
13. Onali, P.; Olianas, M.C.; Gessa, G.L. Selective blockade of dopamine D-1 receptors by SCH 23390 discloses striatal dopamine D-2 receptors mediating the inhibition of adenylate cyclase in rats. Eur. J. Pharmacol., 1984, 99, 127-128.
14. Cooper, D.M.; Bier-Laning, C.M.; Halford, M.K.; Ahlijanian, M.K.; Zahniser, N.R. Dopamine, acting through D-2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process. Mol. Pharmacol., 1986, 29, 113-119.
15. Emilien, G.; Maloteaux, J.M.; Geurts, M.; Hoogenberg, K.; Cragg, S. Dopamine receptors--physiological understanding to therapeutic intervention potential. Pharmacol. Ther., 1999, 84, 133-156.
16. Missale, C.; Nash, S.R.; Robinson, S.W.; Jaber, M.; Caron, M.G. Dopamine receptors: from structure to function. Physiol. Rev., 1998, 78, 189-225.
17. Niznik, H.B.; Van Tol, H.H. Dopamine receptor genes: new tools for molecular psychiatry. J. Psychiatry Neurosci., 1992, 17, 158-180.
18. Civelli, O.; Bunzow, J.R.; Grandy, D.K. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol.Toxicol., 1993, 33, 281-31-307.
19. Monsma, F.J., Jr.; Mahan, L.C.; McVittie, L.D.; Gerfen, C.R.; Sibley, D.R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. USA, 1990, 87, 6723-6727.
20. Sunahara, R.K.; Guan, H.C.; O'Dowd, B.F.; Seeman, P.; Laurier, L.G.; Ng, G.; George, S.R.; Torchia, J.; Van Tol, H.H.; Niznik, H.B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature, 1991, 350, 614-619.
21. Bergson, C.; Mrzljak, L.; Smiley, J.F.; Pappy, M.; Levenson, R.; Goldman-Rakic, P.S. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J. Neurosci., 1995, 15, 7821-7836.
22. Choi, W.S.; Machida, C.A.; Ronnekleiv, O.K. Distribution of dopamine D1, D2, and D5 receptor mRNAs in the monkey brain: ribonuclease protection assay analysis. Brain Res. Mol. Brain Res., 1995, 31, 86-94.
23. Graybiel, A.M.; Aosaki, T.; Flaherty, A.W.; Kimura, M. The basal ganglia and adaptive motor control. Science, 1994, 265, 1826-1831.
24. Goldman-Rakic, P.S.; Castner, S.A.; Svensson, T.H.; Siever, L.J.; Williams, G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl.), 2004, 174, 3-16.
25. Savasta, M.; Dubois, A.; Scatton, B. Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390. Brain Res., 1986, 375, 291-301.
26. Boyson, S.J.; McGonigle, P.; Molinoff, P.B. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci., 1986, 6, 3177-3188.
27. Wamsley, J.K.; Gehlert, D.R.; Filloux, F.M.; Dawson, T.M. Comparison of the distribution of D-1 and D-2 dopamine receptors in the rat brain. J. Chem. Neuroanat., 1989, 2, 119-137.
28. Fremeau, R.T., Jr.; Duncan, G.E.; Fornaretto, M.G.; Dearry, A.; Gingrich, J.A.; Breese, G.R.; Caron, M.G. Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc. Natl. Acad. Sci. USA, 1991, 88, 3772-3776.
29. Mengod, G.; Villaro, M.T.; Landwehrmeyer, G.B.; Martinez-Mir, M.I.; Niznik, H.B.; Sunahara, R.K.; Seeman, P.; O'Dowd, B.F.; Probst, A.; Palacios, J.M. Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem. Int., 1992, 20(Suppl), 33S-43S.
30. Langley, K.C.; Bergson, C.; Greengard, P.; Ouimet, C.C. Colocalization of the D1 dopamine receptor in a subset of DARPP-32 containing neurons in rat caudate-putamen. Neuroscience, 1997, 78, 977-983.
31. Hersch, S.M.; Ciliax, B.J.; Gutekunst, C.A.; Rees, H.D.; Heilman, C.J.; Yung, K.K.; Bolam, J.P.; Ince, E.; Yi, H.; Levey, A.I. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci., 1995, 15, 5222-5237.
32. Alvarez, V.A.; Sabatini, B.L. Anatomical and physiological plasticity of dendritic spines. Annu. Rev. Neurosci., 2007, 30, 79-97.
33. Altar, C.A.; Marien, M.R. Picomolar affinity of 125I-SCH 23982 for D1 receptors in brain demonstrated with digital subtraction autoradiography. J. Neurosci., 1987, 7, 213-222.
34. Berger, K.; Przedborski, S.; Cadet, J.L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull., 1991, 26, 301-307.
35. Cadet, J.L.; Last, R.; Kostic, V.; Przedborski, S.; Jackson-Lewis, V. Long-term behavioral and biochemical effects of 6 hydroxydopamine injections in rat caudate-putamen. Brain Res. Bull., 1991, 26, 707-713.
36. Augood, S.J.; Faull, R.L.; Emson, P.C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol., 1997, 42, 215-221.
37. Weeks, R.A.; Piccini, P.; Harding, A.E.; Brooks, D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol., 1996, 40, 49-54.
38. Deng, Y.P.; Albin, R.L.; Penney, J.B.; Young, A.B.; Anderson, K.D.; Reiner, A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J. Chem. Neuroanat., 2004, 27, 143-164.
39. Kebabian, J.W.; Greengard, P. Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission. Science, 1971, 174, 1346-1349.
40. Clement-Cormier, Y.C.; Kebabian, J.W.; Petzold, G.L.; Greengard, P. Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc. Natl. Acad. Sci. USA, 1974, 71, 1113-1117.
41. Izenwasser, S.; Katz, J.L. Differential efficacies of dopamine D1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur. J. Pharmacol., 1993, 246, 39-44.
42. Dearry, A.; Gingrich, J.A.; Falardeau, P.; Fremeau, R.T., Jr.; Bates, M.D.; Caron, M.G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature, 1990, 347, 72-76.
43. Prasad, K.N.; Gilmer, K.N. Demonstration of dopamine-sensitive adenylate cyclase in malignant neuroblastoma cells and change in sensitivity of adenylate cyclase to catecholamines in differentiated cells. Proc. Natl. Acad. Sci. USA, 1974, 71, 2525-2529.
44. Clement-Cormier, Y.C.; Robison, G.A. Adenylate cyclase from various dopaminergic areas of the brain and the action of antipsychotic drugs. Biochem. Pharmacol., 1977, 26, 1719-1722.
45. Coronas, V.; Krantic, S.; Jourdan, F.; Moyse, E. Dopamine receptor coupling to adenylyl cyclase in rat olfactory pathway: a combined pharmacological-radioautographic approach. Neuroscience, 1999, 90, 69-78.
46. Zhang, J.; Vinuela, A.; Neely, M.H.; Hallett, P.J.; Grant, S.G.; Miller, G.M.; Isacson, O.; Caron, M.G.; Yao, W.D. Inhibition of the dopamine D1 receptor signaling by PSD-95. J. Biol. Chem., 2007, 282, 15778-15789.
47. Mishra, R.K.; Gardner, E.L.; Katzman, R.; Makman, M.H. Enhancement of dopamine-stimulated adenylate cyclase activity in rat caudate after lesions in substantia nigra: evidence for denervation supersensitivity. Proc. Natl. Acad. Sci. USA, 1974, 71, 3883-3887.
48. Krueger, B.K.; Forn, J.; Walters, J.R.; Roth, R.H.; Greengard, P. Stimulation by dopamine of adenosine cyclic 3',5'-monophosphate formation in rat caudate nucleus: effect of lesions of the nigroneostriatal pathway. Mol. Pharmacol., 1976, 12, 639-648.
49. Herve, D.; Levi-Strauss, M.; Marey-Semper, I.; Verney, C.; Tassin, J.P.; Glowinski, J.; Girault, J.A. G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase. J. Neurosci., 1993, 13, 2237-2248.
50. Zhuang, X.; Belluscio, L.; Hen, R. G(olf)alpha mediates dopamine D1 receptor signaling. J. Neurosci., 2000, 20, RC91.
51. Herve, D.; Rogard, M.; Levi-Strauss, M. Molecular analysis of the multiple Golf alpha subunit mRNAs in the rat brain. Brain Res. Mol. Brain Res., 1995, 32, 125-134.
52. Belluscio, L.; Gold, G.H.; Nemes, A.; Axel, R. Mice deficient in G(olf) are anosmic. Neuron, 1998, 20, 69-81.
53. Jones, D.T.; Reed, R.R. Golf: an olfactory neuron specific-G protein involved in odorant signal transduction. Science, 1989, 244, 790-795.
54. Kuroiwa, M.; Bateup, H.S.; Shuto, T.; Higashi, H.; Tanaka, M.; Nishi, A. Regulation of DARPP-32 phosphorylation by three distinct dopamine D1-like receptor signaling pathways in the neostriatum. J. Neurochem., 2008, 107, 1014-1026.
55. Lee, S.P.; So, C.H.; Rashid, A.J.; Varghese, G.; Cheng, R.; Lanca, A.J.; O'Dowd, B.F.; George, S.R. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem., 2004, 279, 35671-35678.
56. Mahan, L.C.; Burch, R.M.; Monsma, F.J., Jr.; Sibley, D.R. Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilization in Xenopus oocytes. Proc. Natl. Acad. Sci. USA, 1990, 87, 2196-2200.
57. Undie, A.S.; Friedman, E. Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J. Pharmacol. Exp. Ther., 1990, 253, 987-992.
58. Wang, H.Y.; Undie, A.S.; Friedman, E. Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. Mol. Pharmacol., 1995, 48, 988-994.
59. Berridge, M.J. Inositol trisphosphate and calcium signaling mechanisms. Biochim. Biophys. Acta, 2009, 1793, 933-940.
60. Jin, L.Q.; Goswami, S.; Cai, G.; Zhen, X.; Friedman, E. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J. Neurochem., 2003, 85, 378-386.
61. Jin, L.Q.; Wang, H.Y.; Friedman, E. Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions. J. Neurochem., 2001, 78, 981-990.
62. Tang, T.S.; Bezprozvanny, I. Dopamine receptor-mediated Ca(2+) signaling in striatal medium spiny neurons. J. Biol. Chem., 2004, 279, 42082-42094.
63. Rashid, A.J.; So, C.H.; Kong, M.M.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O'Dowd, B.F.; George, S.R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. USA, 2007, 104, 654-659.
64. Ma, L.Q.; Liu, C.; Wang, F.; Xie, N.; Gu, J.; Fu, H.; Wang, J.H.; Cai, F.; Liu, J.; Chen, J.G. Activation of phosphatidylinositol linked novel D1 dopamine receptors inhibits high-voltage-activated Ca2+ currents in primary cultured striatal neurons. J. Neurophysiol., 2009, 101, 2230-2238.
65. Wu, J.; Dougherty, J.J.; Nichols, R.A. Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors. J. Neurochem., 2006, 98, 481-494.
66. Lebel, M.; Patenaude, C.; Allyson, J.; Massicotte, G.; Cyr, M. Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways. Neuropharmacology, 2009, 57, 392-402.
67. Jessberger, S.; Gage, F.H.; Eisch, A.J.; Lagace, D.C. Making a neuron: Cdk5 in embryonic and adult neurogenesis. Trends Neurosci., 2009, 32, 575-582.
68. Jayanthi, S.; McCoy, M.T.; Beauvais, G.; Ladenheim, B.; Gilmore, K.; Wood, W.; 3rd, Becker, K.; Cadet, J.L. Methamphetamine induces dopamine D1 receptor-dependent endoplasmic reticulum stress-related molecular events in the rat striatum. PLoS ONE, 2009, 4, e6092.
69. Berke, J.D.; Paletzki, R.F.; Aronson, G.J.; Hyman, S.E.; Gerfen, C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J. Neurosci., 1998, 18, 5301-5310.
70. Berretta, S.; Robertson, H.A.; Graybiel, A.M. Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. J. Neurophysiol., 1992, 68, 767-777.
71. Bhat, R.V.; Baraban, J.M. Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. J. Pharmacol. Exp. Ther., 1993, 267, 496-505.
72. Cole, A.J.; Bhat, R.V.; Patt, C.; Worley, P.F.; Baraban, J.M. D1 dopamine receptor activation of multiple transcription factor genes in rat striatum. J. Neurochem., 1992, 58, 1420-1426.
73. Graybiel, A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci., 1990, 13, 244-254.
74. Konradi, C.; Cole, R.L.; Heckers, S.; Hyman, S.E. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J. Neurosci., 1994, 14, 5623-5634.
75. Moratalla, R.; Robertson, H.A.; Graybiel, A.M. Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum. J. Neurosci., 1992, 12, 2609-2622.
76. Zhang, D.; Zhang, L.; Lou, D.W.; Nakabeppu, Y.; Zhang, J.; Xu, M. The dopamine D1 receptor is a critical mediator for cocaine induced gene expression. J. Neurochem., 2002, 82, 1453-1464.
77. Cadet, J.L.; Jayanthi, S.; McCoy, M.T.; Vawter, M.; Ladenheim, B. Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: Evidence from cDNA array. Synapse, 2001, 41, 40-48.
78. Jayanthi, S.; Deng, X.; Bordelon, M.; McCoy, M.T.; Cadet, J.L. Methamphetamine causes differential regulation of pro-death and anti death Bcl-2 genes in the mouse neocortex. FASEB J, 2001, 15, 1745-1752.
79. Simpson, C.S.; Morris, B.J. Induction of c-fos and zif/268 gene expression in rat striatal neurons, following stimulation of D1-like dopamine receptors, involves protein kinase A and protein kinase C. Neuroscience, 1995, 68, 97-106.
80. Svenningsson, P.; Fienberg, A.A.; Allen, P.B.; Moine, C.L.; Lindskog, M.; Fisone, G.; Greengard, P.; Fredholm, B.B. Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32. J. Neurochem., 2000, 75, 248-257.
81. Nnadi, C.U.; Mimiko, O.A.; McCurtis, H.L.; Cadet, J.L. Neuropsychiatric effects of cocaine use disorders. J. Natl. Med. Assoc., 2005, 97, 1504-1515.
82. Ritz, M.C.; Lamb, R.J.; Goldberg, S.R.; Kuhar, M.J. Cocaine receptors on dopamine transporters are related to self administration of cocaine. Science, 1987, 237, 1219-1223.
83. Hurd, Y.L.; Ungerstedt, U. Cocaine: an in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse, 1989, 3, 48-54.
84. Nestler, E.J. The neurobiology of cocaine addiction. Sci. Pract. Perspect., 2005, 3, 4-10.
85. Cenci, M.A.; Campbell, K.; Wictorin, K.; Bjorklund, A. Striatal cfos induction by cocaine or apomorphine occurs preferentially in output neurons projecting to the substantia nigra in the rat. Eur. J. Neurosci., 1992, 4, 376-380.
86. Zhang, L.; Lou, D.; Jiao, H.; Zhang, D.; Wang, X.; Xia, Y.; Zhang, J.; Xu, M. Cocaine-induced intracellular signaling and gene expression are oppositely regulated by the dopamine D1 and D3 receptors. J. Neurosci., 2004, 24, 3344-3354.
87. Zhang, J.; Zhang, L.; Jiao, H.; Zhang, Q.; Zhang, D.; Lou, D.; Katz, J.L.; Xu, M. c-Fos facilitates the acquisition and extinction of cocaine-induced persistent changes. J. Neurosci., 2006, 26, 13287-13296.
88. Wirtshafter, D.; Osborn, C.V. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats. Eur. J. Pharmacol., 2005, 528, 88-94.
89. Bertran-Gonzalez, J.; Bosch, C.; Maroteaux, M.; Matamales, M.; Herve, D.; Valjent, E.; Girault, J.A. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci., 2008, 28, 5671-5685.
90. Guan, X.; Tao, J.; Li, S. Dopamine D1 receptor, but not dopamine D2 receptor, is a critical regulator for acute cocaine-enhanced gene expression. Neurol. Res., 2009, 31, 17-22.
91. Jouvert, P.; Dietrich, J.B.; Aunis, D.; Zwiller, J. Differential rat brain expression of EGR proteins and of the transcriptional corepressor NAB in response to acute or chronic cocaine administration. Neuromol. Med., 2002, 1, 137-151.
92. Dopheide, J.A.; Pliszka, S.R. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy, 2009, 29, 656-679.
93. Gold, M.S.; Kobeissy, F.H.; Wang, K.K.; Merlo, L.J.; Bruijnzeel, A.W.; Krasnova, I.N.; Cadet, J.L. Methamphetamine and trauma induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol. Psychiatry, 2009, 66, 118-127.
94. Krasnova, I.N.; Cadet, J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev., 2009, 60, 379-407.
95. Wang, J.Q.; Smith, A.J.; McGinty, J.F. A single injection of amphetamine or methamphetamine induces dynamic alterations in c-fos, zif/268 and preprodynorphin messenger RNA expression in rat forebrain. Neuroscience, 1995, 68, 83-95.
96. Jayanthi, S.; McCoy, M.T.; Ladenheim, B.; Cadet, J.L. Methamphetamine causes coordinate regulation of SRC, cas, crk, and the jun N-terminal kinase-jun pathway. Mol. Pharmacol., 2002, 61, 1124-1131.
97. Herdegen, T.; Waetzig, V. AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene, 2001, 20, 2424-2437.
98. Shaulian, E.; Karin, M. AP-1 as a regulator of cell life and death. Nat. Cell Biol., 2002, 4, E131-136.
99. Beckmann, A.M.; Wilce, P.A. Egr transcription factors in the nervous system. Neurochem. Int., 1997, 31, 477-510; discussion 517-476.
100. Wang, J.Q.; McGinty, J.F. Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine or methamphetamine-induced up-regulation of zif/268 mRNA expression in rat forebrain. J. Neurochem., 1995, 65, 2706-2715.
101. Li, Q.X.; Ke, N.; Sundaram, R.; Wong-Staal, F. NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol. Histopathol., 2006, 21, 533-540.
102. Green, T.A.; Alibhai, I.N.; Hommel, J.D.; DiLeone, R.J.; Kumar, A.; Theobald, D.E.; Neve, R.L.; Nestler, E.J. Induction of inducible cAMP early repressor expression in nucleus accumbens by stress or amphetamine increases behavioral responses to emotional stimuli. J. Neurosci., 2006, 26, 8235-8242.
103. Thomas, D.M.; Francescutti-Verbeem, D.M.; Liu, X.; Kuhn, D.M. Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment--an oligonucleotide microarray approach. J. Neurochem., 2004, 88, 380-393.
104. Molina, C.A.; Foulkes, N.S.; Lalli, E.; Sassone-Corsi, P. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell, 1993, 75, 875-886.
105. Tinti, C.; Conti, B.; Cubells, J.F.; Kim, K.S.; Baker, H.; Joh, T.H. Inducible cAMP early repressor can modulate tyrosine hydroxylase gene expression after stimulation of cAMP synthesis. J. Biol. Chem., 1996, 271, 25375-25381.
106. Svaren, J.; Sevetson, B.R.; Apel, E.D.; Zimonjic, D.B.; Popescu, N.C.; Milbrandt, J. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol. Cell Biol., 1996, 16, 3545-3553.
107. Kumbrink, J.; Gerlinger, M.; Johnson, J.P. Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop. J. Biol. Chem., 2005, 280, 42785-42793.
108. Nguyen, T.; Di Giovanni, S. NFAT signaling in neural development and axon growth. Int. J. Dev. Neurosci., 2008, 26, 141-145.
109. Jayanthi, S.; Deng, X.; Ladenheim, B.; McCoy, M.T.; Cluster, A.; Cai, N.S.; Cadet, J.L. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine induced neuronal apoptosis. Proc. Natl. Acad. Sci. USA, 2005, 102, 868-873.
110. Groth, R.D.; Weick, J.P.; Bradley, K.C.; Luoma, J.I.; Aravamudan, B.; Klug, J.R.; Thomas, M.J.; Mermelstein, P.G. D1 dopamine receptor activation of NFAT-mediated striatal gene expression. Eur. J. Neurosci., 2008, 27, 31-42.
111. Graybiel, A.M. The basal ganglia: learning new tricks and loving it. Curr. Opin. Neurobiol., 2005, 15, 638-644.
112. Angulo, J.A.; McEwen, B.S. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. Brain Res. Brain Res. Rev., 1994, 19, 1-28.
113. Augood, S.J.; Westmore, K.; Faull, R.L.; Emson, P.C. Neuroleptics and striatal neuropeptide gene expression. Prog. Brain Res., 1993, 99, 181-199.
114. Sonsalla, P.K.; Gibb, J.W.; Hanson, G.R. Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation. Eur. J. Pharmacol., 1984, 105, 185-187.
115. Engber, T.M.; Boldry, R.C.; Kuo, S.; Chase, T.N. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res., 1992, 581, 261-268.
116. Wang, J.Q.; McGinty, J.F. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. J. Pharmacol. Exp. Ther, 1997, 281, 972-982.
117. Oblin, A.; Zivkovic, B.; Bartholini, G. Selective antagonists of dopamine receptor subtypes differentially affect substance P levels in the striatum and substantia nigra. Brain Res., 1987, 421, 387-390.
118. Campbell, B.M.; Walker, P.D. Striatal preprotachykinin mRNA levels are regulated by stimulatory agents and dopamine D1 receptor manipulation in rodent organotypic slice cultures. Brain Res., 2001, 888, 26-33.
119. Mao, L.; Conquet, F.; Wang, J.Q. Impaired preprodynorphin, but not preproenkephalin, mRNA induction in the striatum of mGluR1 mutant mice in response to acute administration of the full dopamine D(1) agonist SKF-82958. Synapse, 2002, 44, 86-93.
120. Campbell, B.M.; Kreipke, C.W.; Walker, P.D. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine depleted rat. Neuroscience, 2006, 137, 505-517.
121. Hanson, G.R.; Bush, L.; Keefe, K.A.; Alburges, M.E. Distinct responses of basal ganglia substance P systems to low and high doses of methamphetamine. J. Neurochem., 2002, 82, 1171-1178.
122. St-Gelais, F.; Jomphe, C.; Trudeau, L.E. The role of neurotensin in central nervous system pathophysiology: what is the evidence? J. Psychiatry Neurosci., 2006, 31, 229-245.
123. Caceda, R.; Kinkead, B.; Nemeroff, C. In: Peptides: Neurotensin, role in psychiatric and neurological diseases; 2006; vol. 27, pp. 2385-2404.
124. Merchant, K.M.; Letter, A.A.; Gibb, J.W.; Hanson, G.R. Changes in the limbic neurotensin systems induced by dopaminergic drugs. Eur. J. Pharmacol., 1988, 153, 1-9.
125. Hanson, G.R.; Keefe, K.A. Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway. Brain Res. Mol. Brain Res., 1999, 66, 111-121.
126. St-Hilaire, M.; Landry, E.; Levesque, D.; Rouillard, C. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism. Neurobiol. Dis., 2005, 20, 450-460.
127. Thiriet, N.; Deng, X.; Solinas, M.; Ladenheim, B.; Curtis, W.; Goldberg, S.R.; Palmiter, R.D.; Cadet, J.L. Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J. Neurosci., 2005, 25, 5273-5279.
128. Westwood, S.C.; Hanson, G.R. Effects of stimulants of abuse on extrapyramidal and limbic neuropeptide Y systems. J. Pharmacol. Exp. Ther., 1999, 288, 1160-1166.
129. Horner, K.A.; Westwood, S.C.; Hanson, G.R.; Keefe, K.A. Multiple high doses of methamphetamine increase the number of preproneuropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism. J. Pharmacol. Exp. Ther., 2006, 319, 414-421.
130. Robinson, T.E.; Kolb, B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology, 2004, 47(Suppl 1), 33-46.
131. Fujiyama, K.; Kajii, Y.; Hiraoka, S.; Nishikawa, T. Differential regulation by stimulants of neocortical expression of mrt1, arc, and homer1a mRNA in the rats treated with repeated methamphetamine. Synapse, 2003, 49, 143-149.
132. Kodama, M.; Akiyama, K.; Ujike, H.; Shimizu, Y.; Tanaka, Y.; Kuroda, S. A robust increase in expression of arc gene, an effector immediate early gene, in the rat brain after acute and chronic methamphetamine administration. Brain Res., 1998, 796, 273-283.
133. Kuppers, E.; Beyer, C. Dopamine regulates brain-derived neurotrophic factor (BDNF) expression in cultured embryonic mouse striatal cells. Neuroreport, 2001, 12, 1175-1179.
134. Williams, S.N.; Undieh, A.S. Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression. Neuroreport, 2009, 20, 606-610.
135. Gonzalez, A.M.; Berry, M.; Maher, P.A.; Logan, A.; Baird, A. A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain. Brain Res., 1995, 701, 201-226.
136. Zhang, X.; Zhou, Z.; Wang, D.; Li, A.; Yin, Y.; Gu, X.; Ding, F.; Zhen, X.; Zhou, J. Activation of phosphatidylinositol-linked D1 like receptor modulates FGF-2 expression in astrocytes via IP3 dependent Ca2+ signaling. J. Neurosci., 2009, 29, 7766-7775.
137. Xi, Z.X.; Kleitz, H.K.; Deng, X.; Ladenheim, B.; Peng, X.Q.; Li, X.; Gardner, E.L.; Stein, E.A.; Cadet, J.L. A single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats. Neuroscience, 2009, 161, 392-402.
138. Butcher, S.P.; Fairbrother, I.S.; Kelly, J.S.; Arbuthnott, G.W. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem., 1988, 50, 346-355.
139. Hattori, A.; Luo, Y.; Umegaki, H.; Munoz, J.; Roth, G.S. Intrastriatal injection of dopamine results in DNA damage and apoptosis in rats. Neuroreport, 1998, 9, 2569-2572.
140. Luo, Y.; Hattori, A.; Munoz, J.; Qin, Z.H.; Roth, G.S. Intrastriatal dopamine injection induces apoptosis through oxidation involved activation of transcription factors AP-1 and NF-kappaB in rats. Mol. Pharmacol., 1999, 56, 254-264.
141. Cheng, N.; Maeda, T.; Kume, T.; Kaneko, S.; Kochiyama, H.; Akaike, A.; Goshima, Y.; Misu, Y. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res., 1996, 743, 278-283.
142. Shinkai, T.; Zhang, L.; Mathias, S.A.; Roth, G.S. Dopamine induces apoptosis in cultured rat striatal neurons; possible mechanism of D2-dopamine receptor neuron loss during aging. J. Neurosci. Res., 1997, 47, 393-399.
143. McLaughlin, B.A.; Nelson, D.; Erecinska, M.; Chesselet, M.F. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem., 1998, 70, 2406-2415.
144. Iwatsubo, K.; Suzuki, S.; Li, C.; Tsunematsu, T.; Nakamura, F.; Okumura, S.; Sato, M.; Minamisawa, S.; Toya, Y.; Umemura, S.; Ishikawa, Y. Dopamine induces apoptosis in young, but not in neonatal, neurons via Ca2+-dependent signal. Am. J. Physiol. Cell. Physiol., 2007, 293, C1498-1508.
145. Rosenberg, P.A. Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci., 1988, 8, 2887-2894.
146. Tanaka, M.; Sotomatsu, A.; Kanai, H.; Hirai, S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J. Neurol. Sci., 1991, 101, 198-203.
147. Mytilineou, C.; Han, S.K.; Cohen, G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J. Neurochem., 1993, 61, 1470-1478.
148. Hoyt, K.R.; Reynolds, I.J.; Hastings, T.G. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp. Neurol., 1997, 143, 269-281.
149. Luo, Y.; Umegaki, H.; Wang, X.; Abe, R.; Roth, G.S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem., 1998, 273, 3756-3764.
150. Jones, D.C.; Gunasekar, P.G.; Borowitz, J.L.; Isom, G.E. Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J. Neurochem., 2000, 74, 2296-2304.
151. Graham, D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol., 1978, 14, 633-643.
152. Graham, D.G.; Tiffany, S.M.; Bell, W.R., Jr.; Gutknecht, W. F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol., 1978, 14, 644-653.
153. Cadet, J.L.; Brannock, C. Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int., 1998, 32, 117-131.
154. Wersinger, C.; Chen, J.; Sidhu, A. Bimodal induction of dopamine mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation. Mol. Cell. Neurosci., 2004, 25, 124-137.
155. Chen, J.; Wersinger, C.; Sidhu, A. Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity. J. Biol. Chem., 2003, 278, 28089-28100.
156. Chen, J.; Rusnak, M.; Luedtke, R.R.; Sidhu, A. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J. Biol. Chem., 2004, 279, 39317-39330.
157. Deng, X.; Cadet, J.L. Methamphetamine administration causes overexpression of nNOS in the mouse striatum. Brain Res., 1999, 851, 254-257.
158. Zhu, J.P.; Xu, W.; Angulo, J.A. Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice. Neuroscience, 2006, 140, 607-622.
159. Jayanthi, S.; Deng, X.; Noailles, P.A.; Ladenheim, B.; Cadet, J.L. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J., 2004, 18, 238-251.
160. Aramburu, J.; Heitman, J.; Crabtree, G.R. Calcineurin: a central controller of signalling in eukaryotes. EMBO Rep., 2004, 5, 343-348.
161. Asai, A.; Qiu, J.; Narita, Y.; Chi, S.; Saito, N.; Shinoura, N.; Hamada, H.; Kuchino, Y.; Kirino, T. High level calcineurin activity predisposes neuronal cells to apoptosis. J. Biol. Chem., 1999, 274, 34450-34458.
162. O'Sullivan, G.J.; Clifford, J.J.; Tomiyama, K.; Koshikawa, N.; Drago, J.; Sibley, D.R.; Croke, D.T.; Waddington, J.L. D1-like dopamine receptor-mediated function in congenic mutants with D1 vs D5 receptor knockout. J. Recept. Signal Transduct. Res., 2004, 24, 107-116.